Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
A Second Controversial Duchenne Approval For Company
Executive Summary
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
You may also be interested in...
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone
Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.
The 2010s: A Decade Of Acceleration, Innovation And Controversy
A look back at some of the defining events and trends in pharma over the past 10 years.